Is NCT06424067 recruiting in Charleston, SC?

Yes, NCT06424067 is currently recruiting participants at its Charleston, SC location. This non small cell lung cancer clinical trial is actively enrolling qualified participants.

How do I join the non small cell lung cancer clinical trial in Charleston?

To join this clinical trial in Charleston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Charleston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non Small Cell Lung Cancer Clinical Trial in Charleston, SC

About This Non Small Cell Lung Cancer Study in Charleston

This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.

Sponsor: Medical University of South Carolina

Who Can Participate

Inclusion Criteria

Voluntary, signed, and dated, Institutional Review Board (IRB) approved consent form in accordance with regulatory and institutional guidelines.

Stated willingness to comply with all study procedures and availability for the duration of the study.

Male or female

18 years of age or older

Measurable/evaluable as defined by RECIST 1.1 at baseline of advanced/metastatic non-small cell lung cancer progressed on 2L+ systemic therapy with any molecular subtype and PD-L1 Tumor Proportion Score (TPS).

Measurable/evaluable as defined by RECIST 1.1 at baseline of extensive stage small cell lung cancer progressed on 2L+ systemic therapy.

Ability to take oral medication and be willing to adhere to the fingolimod regimen.

ECOG performance status 0-2

Baseline lymphocyte count \>1000 cells/mL

For females of reproductive potential: use of highly effective contraception for at least 1 month before screening and agreement to use such a method during study participation and for an additional 2 months after the end of fingolimod administration.

For males of reproductive potential: use of condoms or other methods during and for an additional 2 months after the end of fingolimod treatment to ensure effective contraception with a partner.

Exclusion Criteria

Patients who have had a recent (within the last 6 months) occurrence of cardiac event including myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or New York Heart Association Class III or IV heart failure, and congenital long QT-syndrome

Patients who are receiving any medication(s) identified as having a Category D or higher interaction with the identified study agent who cannot be switched to another agent or discontinued before treatment if clinically appropriate. This medication review will be conducted by an oncology-trained Doctor of Pharmacy and discussed with the investigators before starting the treatment phase of this study. Careful evaluation for the following class of medications should be warranted due to their potential for severe side effects:

Concurrent therapy with QT-prolonging medications with a known risk of torsade de pointes

Concurrent therapy with drugs that slow heart rate or atrioventricular conduction

Concurrent therapy with antineoplastic, immunosuppressive, or immune-modulating therapies

Patients taking ketoconazole who have not completed their last dose at least 2 weeks before starting fingolimod.

Active untreated brain metastases. Patients are eligible if brain metastases are previously treated and are asymptomatic. Patients must be neurologically stable and must be on stable or tapering corticosteroids 2 weeks before Cycle 1 Day 1

Patients who have a history or presence of Mobitz Type II 2nd-degree or 3rd-degree atrioventricular block or sick sinus syndrome, unless patients have a functioning pacemaker.

Patients who have a baseline QTc interval ≥ 500 msec

Patients who have cardiac arrhythmias requiring Class IA or Class III anti-arrhythmic drugs.

Class IA: disopyramide (Norpace), quinidine (Quinidex), procainamide (Procanbid)

Class III: dronedarone (Multaq), dofetilide (Tikosyn), sotalol (Betapace), ibutilide (Corvert), amiodarone (Nexterone)

Patients who have a hypersensitivity or allergic reaction (including rash, urticaria, and angioedema) to fingolimod or any of the excipients.

Patients who have an active, uncontrolled acute or chronic bacterial, viral, or fungal infection

Patients who have not completed all immunizations in accordance with current immunization guidelines before initiating fingolimod therapy

Unwillingness or inability to comply with procedures required in this protocol.

Patients who are currently participating in any other clinical trial of an investigational product

Female patients who are of child-bearing potential (WOCBP) who are pregnant, planning to become pregnant during the study, or lactating. A urine pregnancy test for WOCBP will be collected during the screening period. Females will be determined to be not of child-bearing potential with a history of hysterectomy, tubal ligation, or age 45 or older with postmenopausal status \> 12 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Charleston?

Yes, this clinical trial (NCT06424067) has an active research site in Charleston, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non Small Cell Lung Cancer Treatment Options in Charleston, SC

If you're searching for non small cell lung cancer treatment options in Charleston, SC, this clinical trial (NCT06424067) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Charleston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

Non Small Cell Lung Cancer Clinical Trial in Charleston, SC

Expert Care in Charleston

IRB Approved

No-Cost Care

Apply for This Charleston Location

Why Participate?

Simple Process